This was a retrospective cohort study to identify the rates, predictors, and outcomes of health care-associated bloodstream infections (HA-BSI) among children with solid tumors, lymphoma, lymphoid leukemia, and myeloid leukemia. The study population included 4500 children ≤18 years old at a pediatric hospital in New York City from 2006 to 2014. A total of 147 HA-BSI cases were identified; using multivariable logistic regression modeling, children with a hematologic diagnosis (lymphoma, lymphoid leukemia, myeloid leukemia) were at greater risk for HA-BSI than those with a solid tumor diagnosis (all P values <.0001). The odds of mortality for patients with HA-BSI were 6.98 (95% confidence interval 3.02-16.10) times that of those without HA-BSI. Although malignancy type was identified as risk factor for HA-BSI, there was no significant difference in overall mortality from HA-BSI by tumor type (P = .51).
Introduction
Health care-associated infections (HAIs) are a serious public health concern, increasing mortality, morbidity, and overall hospital costs (Siddiqui, Wali, Haque, & Fadoo, 2012) . According to the most recent prevalence survey conducted by the Centers for Disease Control and Prevention (CDC), every day, 1 in 25 in-patients will develop an HAI (Magill et al., 2014) . In 2011 alone, there were approximately 722 000 HAIs (4.0% prevalence) in acute care hospitals and about 75 000 of those patients died during hospitalization (Magill et al., 2014) . Despite declining rates in most types of HAIs, health careassociated bloodstream infections (HA-BSI) remain a serious threat (CDC, 2013) .
To date, few studies of HA-BSI have focused specifically on pediatric cancer patients, despite the fact that these patients present a different subset of risks then their adult counterparts and are at an overall increased risk for HAI. In a study by Safdar et al. (2015) , pediatrics was identified as an area in need of better surveillance research because of unique risk factors inherent in the population. Of the HAI infections reported in the CDC prevalence survey, 8% were in patients less than 1 year old, and 4.2% of patients were 17 years old or younger (Magill et al., 2014) . The study did not stratify by age groups among children despite the fact that immune function among pediatric patients is often age-dependent and risk of HAI may vary significantly among age groups (Safdar et al., 2015) . Patients with an oncologic diagnosis face an even greater risk because of their diminished immunocapacity, prevalence of neutropenia, receipt of high-risk drugs, frequent hospital admissions with prolonged lengths of stay, and potential requirement of extended central venous access (Kelly et al., 2011) . The National Healthcare Safety Network identified pooled mean rates of deviceassociated blood stream and urinary infections among hematology/oncology pediatric patients that were much higher than the rates of their adult counterparts in the same type of unit and especially higher than the rates of all other inpatient units with the exception of patients with extensive burns (Dudeck et al., 2013) 680596J POXXX10.1177/1043454216680596Journal of Pediatric Oncology NursingThurman et al.
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1 Columbia University, New York, NY, USA Although some studies have established that malignancies present a higher risk for HAI, very few have examined the epidemiology and comparative risks of HA-BSI among neoplasia type. This study sought to identify subgroups of the pediatric oncology population at increased risk for HAI. Therefore, the specific aims of this study were to (1) identify the rates, predictors, and outcomes of HA-BSI among children with solid tumors, lymphoma, lymphoid leukemia, and myeloid leukemia and (2) describe causal organisms and prevalence of antibiotic resistance for HA-BSI among children with solid tumors, lymphoma, lymphoid leukemia, and myeloid leukemia.
Method

Study Design and Data Collection
This was a retrospective cohort study focusing on the risk factors for HA-BSI with data derived from an National Institutes of Health-funded study (Health Information Technology-Healthcare Associated Infections, 2R01NR010822). The Columbia University Medical Center Institutional Review Board approved this study. Data were collected using electronically available data from about 20 sources: laboratory results including microscopy and microbiologic results; patient location, including hospital unit, room and bed occupied for each day of hospital stay as well as patient's home address; operating room data; clinician orders, and detailed accounts of medications administered and procedures. A full description of data collection and extraction methods were previously published in Apte et al. (2011) . Data were obtained for the years 2006 to 2014 from among those discharged from a tertiary/quaternary care children's hospital in Manhattan with approximately 200 pediatric beds, 50 neonatal beds, 27 pediatric intensive care unit beds, and about 18 000 discharges per year. During the 9-year study period there were 152 585 patient discharges and 2384 had HAIs including urinary tract infection, blood stream infection, surgical site infection, and pneumonia. Patients were included if they were ≤18 years old with 1 or more qualifying ICD-9 (International Classification of Diseases, 9th Revision) oncologic diagnoses present on admission (N = 4526); 26 children with a diagnosis of "other leukemia" and/or "multiple myeloma" were omitted from analysis, for a total sample number of 4500.
Health Care-Associated Bloodstream Infections
HA-BSI cases were defined based on the National Healthcare Safety Network definitions (CDC, 2013) and an algorithm developed and validated from the parent study's electronic database (see Figure 1 ).
Health Care-Associated Bloodstream Infection Organisms
Five organisms associated frequently with HA-BSI were included in the analysis: Acinetobacter baumannii, Enterococcus faecalis/faecium, Klebsiella pneumoniae, Pseudomonas aeruginosa, Staphylococcus aureus. These organisms were further categorized as antibiotic resistant or susceptible based on resistance to the following antibiotics for each organism: A baumannii: ampicillin and ampicillin/sulbactam; E faecalis/ faecium: vancomycin; K pneumoniae: imipenem/ meropenem; P aeruginosa: levofloxacin; S aureus: oxacillin. Of the HA-BSIs identified in this study, 69.4% involved an organism of interest and 60.5% of HA-BSIs identified had data regarding the sensitivity and resistance of the organism of interest. First culture result with a specific organism and resistance pattern = BSI with that organism of interest 
Malignancy Category
Patients were divided into 4 primary malignancy categories: solid tumors, lymphomas, lymphoid leukemias, and myeloid leukemias. These categories were generated using ICD-9 diagnoses and confirmed for validity with a pediatric oncology researcher and nurse practitioner.
Risk Factors
Potential risk factors for HA-BSI were determined through a comprehensive review of literature pertaining to HA-BSI. Common risk factors assessed included level of acuity, presence of indwelling central venous line predating HA-BSI, length of time of existing central venous line, low neutrophil count, receipt of immunosuppressive and chemotherapy agents, hematopoietic stem cell transplant, and comorbid conditions. The information provided in this database allowed for the inclusion of several of these risk factors identified in the literature.
Comorbidities at admission were calculated by using the weighted Charlson comorbidity index (CCI; Charlson, Pompei, Ales, & Mackenzie, 1987) . Year and patient age during hospital stay were included as well. Length of stay, central line, and receipt of immunosuppressive and chemotherapy agents were examined as potential confounders, mediators, or effect modifiers for overall stay and then further modeled as both continuous and dichotomous variables to be analyzed if they occurred prior to an HA-BSI event. Length of stay was modeled as a continuous variable.
Data Analysis
All data were analyzed using SAS 9.4 64 bit for Windows. Risk factors were first examined using 2-way tabular analysis. Patient age was examined on both continuous and categorical scales. Age categories were determined using standard age groupings found in a similar study (Simon et al., 2008) . A dichotomous score for CCI (noneto-low, 0-2, moderate-to-high, 3-5) was used in the final analysis because of a low number of patients in the "high risk" category. Variables prior to onset of infection (for cases) or for entire length of stay (for children without infection) that were continuous, including central line days, days of receipt of chemotherapeutic or immunosuppressive therapy, age, and length of stay, were examined using t tests or analysis of variance as appropriate. Chemotherapeutic and immunosuppressive therapy medications were combined into1 variable named "high-risk medications." Categorical variables were examined using chi-square or Fisher exact tests as appropriate. Risk factors significant in bivariable analyses (P < .05) were included in multiple logistic regression models generated using manual forward selection and likelihood ratio tests. The stability of the standard errors of predictors and the AIC (Akaike information criterion) numbers were also monitored throughout the modeling process. The Cochran-Armitage trend test was used to determine whether there were significant changes in HA-BSI rates between the years 2006 and 2014. Year of hospital stay was then dichotomized into years 2006-2009 and 2010-2014 . Risk factor covariates in the regression models were additionally assessed for interaction on the multiplicative scale using cross-variable terms created for interaction. A separate regression model was fitted to compare the odds of mortality in pediatric oncology patients with an HA-BSI compared to those in the same population without an HA-BSI. Two-way tabular analyses were conducted for risk factors for mortality such as CCI (continuous and binary), age (continuous and categorical), and oncologic diagnosis.
Results
There were 2727 patients with solid tumors, 889 patients with lymphoid leukemia, 531 patients with lymphoma, and 353 with myeloid leukemia (total = 4500 study patients). There were a total of 147 HA-BSI cases during the study period. Patients with and without HA-BSI were similar in age distribution, sex, and race. Significantly more patients with HA-BSI received Medicare/Medicaid than those who did not have HA-BSI (Table 1) .
Risk Factors
On evaluation of potential risk factors, several were identified to have a significant impact on the development of HA-BSI. Of the 147 cases of HA-BSI, 100 central lines were placed prior to HA-BSI or discharge for those without HA-BSI. The total number of central line days for all patients throughout the study period was 20 698 days. The total number of central line days for patients prior to HA-BSI or prior to discharge for those without HA-BSI was 17 637 days. The attack rate of HA-BSI was 5.7 (100/17 637) per 1,000 central line days for those who had a central line before HA-BSI or discharge for those without HA-BSI. The mean number of days (total and before HA-BSI) receiving chemotherapeutic and immunosuppressive drugs were highest for those with myeloid leukemia diagnosis (10.5) and lowest for those with a solid tumor diagnosis (2.4). Similar results were observed for length of stay and central line days (total and before HA-BSI)-children with myeloid leukemia had the highest mean number of days and those with solid tumors had the lowest. Children with a solid tumor diagnosis had the highest proportion of those belonging to the moderate-tohigh risk CCI category than none-to-low (Table 2 ). The age category of the children was also significantly related to both HA-BSI and also malignancy category-patients who were 15+ years old had the highest proportion of HA-BSI in their age category (P = .016).
Length of stay was significantly related to HA-BSI (P < .0001). The mean total central line days for malignancy groups were significantly different between groups (P < .001). Central line days prior to HA-BSI for infected patients or at discharge for patients without HA-BSI were also significantly related to HA-BSI (P < .0001) and significantly different by oncologic diagnoses (P <.0001). Days of receipt of chemotherapeutic or immunosuppressive medications (total and before event) and length of stay (total and before event) were also significantly related to both the outcome (HA-BSI) and oncologic diagnosis and are summarized in Table 3 . A higher categorical CCI score, indicative of more comorbidities, was a significant risk factor for HA-BSI (P = .008); the odds of getting an HA-BSI among those in the CCI category of "moderate-to-high" were 1.6 times that of those in the CCI category of "none-to-low" (95% confidence interval [CI] = 1.2-2.2). CCI category was also significantly related to oncologic diagnosis (P < .0001). Because CCI was significantly related to both HA-BSI and oncologic diagnosis it was controlled for in the final analysis by incorporating it into the regression model.
The rates of HA-BSI steadily declined by year of hospital stay through 2006-2014 from a maximum of 26 cases in 2006 to a minimum of 4 cases in 2014. The Cochran-Armitage test indicated that this decrease in rate of HA-BSI over the study period was significant (P = .0008). It is also of note that the year of hospital stay was significantly related to the malignancy category as well (P = .0006). There were more patients with a diagnosis of solid tumor and lymphoid leukemia between 2010 and 2014 than between 2006 to 2009, whereas there were fewer patients with a diagnosis of lymphoma and myeloid leukemia between 2010 and 2014 than between 2006 and 2009.
Regression Analysis
In the final model, malignancy category was significantly related to the odds of developing an HA-BSI during the hospital stay; patients with myeloid leukemia had higher odds of HA-BSI (odds ratio [OR] = 8.1, 95% CI = 5.0-13.2) compared with those with solid tumors, even when controlling for CCI, receipt of high-risk medications, and year of infection, presence of a central line or length of stay prior to infection. The odds of HA-BSI were also higher for patients with lymphoid leukemia (OR = 3.8, 95% CI = 2.14-6.1) and those with lymphoma (OR = 3.1, 95% CI = 1.8-5.3) as compared with those with a solid tumor diagnosis. Child's age was not a significant predictor of HA-BSI when oncologic diagnosis was included in the model. Further rates of HA-BSI were not significantly different between the years of 2006-2008 and 2009-2012 . None of the variables left in the final model had significant interaction on the multiplicative scale. Results of the final regression model are summarized in Table 3 .
Mortality Analysis
HA-BSI was a significant predictor of mortality; the odds of mortality for pediatric oncology patients with HA-BSI were 6.98 (95% CI: 3.02-16.10) times that of those without HA-BSI when accounting for CCI category. CCI category was also a significant predictor of mortality (P < .0001). Neither oncologic diagnosis (P = .51) nor age (P = .14) was significantly related to HA-BSI or death.
Organisms Causing HA-BSI
Of the 147 cases of HA-BSI, 41 were caused by 1 of the 5 organisms under study. K pneumoniae was the most commonly identified organism identified in the cases of HA-BSI, 13.6% (20/147) of HA-BSI cases. Enterococcus was identified in 8.2% (12/147) HA-BSI cases. The organism associated with the fewest HA-BSI cases was Acintobacter at 0.7% (1/147). Fisher's exact test for differences between the frequencies of HA-BSI organisms was significant (P = .006). Enterococci were the most likely to be antimicrobial resistant (50%, 6/12), followed by K pneumoniae at 40% (8/20). 
Discussion
In our population, the type of oncologic diagnosis had an impact on a pediatric patient's risk for HA-BSI. Oncology patients are already at risk for HA-BSI, therefore, identifying subgroups within this population at higher risk could have implications for how prevention protocols are designed and implemented. Even when major known risk factors such as comorbidities, length of stay, and central line presence are accounted for, those patients with a myeloid leukemia diagnosis remained at the highest risk for HA-BSI, although risk of mortality was not significantly increased. Because, to our knowledge, this is one of the first studies to focus on the difference in risk of HA-BSI associated with malignancy type, there are few studies that are similar enough to draw comparisons. A multicenter study examining the incidence of central line-associated blood stream infections (CLABSIs) in the pediatric population found that the patients in their cohort with CLABSIs were more likely to have acute myeloid leukemia among other risk factors (Gaur et al., 2013) . One limitation of note in the Gaur et al. (2013) study is that the only statistical methods used for comparison were descriptive and did not examine in depth the statistical risks associated with the leukemia to HA-BSI relationship. The authors did, however, similarly conduct culprit organism analyses. While the authors examined a larger spectrum of causal organisms than our study, they did identify Klebsiella pneumoniae in the top 5 of the gram-negative group (Gaur et al., 2013) .
Another study by Hord et al. (2016) demonstrated differences in CLABSI rates in pediatric oncology patients by type of central line. Similar to our study, Hord et al. (2016) stratified patients based on primary hematology/ oncology diagnosis and found that among other risk factors, patients with a tunneled externalized catheter CLABSI were likely to have acute myeloid leukemia (Hord et al., 2016) . The authors also identified Klebsiella in the list of top 5 organisms isolated during CLABSI events in all type of central lines (Hord et al., 2016) .
Limitations
There are limitations to this study, which must be considered when interpreting the results. Most importantly, we were limited in this analysis to the data electronically available. For example, although mucosal barrier injury, hematopoietic stem cell transplant, and neutropenia have been shown to be risk factors for blood stream infection (Kelly et al., 2011; Mollee et al., 2011) , it was not possible in our database to confirm whether they occurred before development of an HAI. Additionally, we only examined HAIs associated with the most common organisms causing HA-BSIs in this study site; further research is needed to assess the relationship between type of cancer and other causes and sites of HAIs, such as Clostridium difficile, urinary tract infection, and health care-acquired pneumonia in the pediatric population.
Relevance to Clinical Practice
Despite these limitations, this study has provided data that confirms that children with different malignancy types may be at variable risk for HAI. Providing evidence displaying the spectrum of HA-BSI risk among pediatric oncology patients may be useful for anticipating which children may be at particularly high risk for infection. If clinicians can anticipate special risks unique to malignancies, planning infection prevention and control strategies might be improved and updated. The findings in this research article can also inspire new hypotheses and further studies to help prevent more HA-BSI in this population.
Conclusion
While pediatric patients with an oncologic or hematologic diagnosis are at serious risk for HA-BSI, research about the difference in risks in this population is limited. This cohort of patients displayed similar patterns of risk found in other research articles, such as a myeloid leukemia diagnosis being a major risk factor for HA-BSI. The large proportion of Klebsiella infection in patients with identifiable organisms also echoes the pattern of research reports currently available, demonstrating that Klebsiella is a major source of HA-BSI in hospitalized pediatric hematology/oncology patients. While this study has limitations, its contribution to the field of pediatric oncology is significant. Because HA-BSI risk can differ between malignancies, new research should also seek to stratify oncology patients by their malignancy diagnosis in order to capture risk accurately. We hope that this study inspires more research to be done on HA-BSI in this population and to make an impact on the overall rates of HA-BSI occurrence.
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